Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
haematologica, 2006 - haematologica.org
BACKGROUND AND OBJECTIVES: Iron accumulation is an inevitable consequence of
chronic blood transfusions and results in serious complications in the absence of chelation …
chronic blood transfusions and results in serious complications in the absence of chelation …
[PDF][PDF] Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - researchgate.net
Patients with chronic anemias such as tha-lassemia, sickle cell disease, congenital rare
anemias and myelodysplastic syndromes require regular blood transfusions in order to …
anemias and myelodysplastic syndromes require regular blood transfusions in order to …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
A Piga, R Galanello, GL Forni… - …, 2006 - pubmed.ncbi.nlm.nih.gov
Background and objectives Iron accumulation is an inevitable consequence of chronic blood
transfusions and results in serious complications in the absence of chelation treatment to …
transfusions and results in serious complications in the absence of chelation treatment to …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - air.unimi.it
Abstract Background and Objectives. Iron accumulation is an inevitable consequence of
chronic blood transfusions and results in serious complications in the absence of chelation …
chronic blood transfusions and results in serious complications in the absence of chelation …
[PDF][PDF] Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - academia.edu
Patients with chronic anemias such as tha-lassemia, sickle cell disease, congenital rare
anemias and myelodysplastic syndromes require regular blood transfusions in order to …
anemias and myelodysplastic syndromes require regular blood transfusions in order to …
[引用][C] Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia …
A PIGA - Haematologica, 2006 - cir.nii.ac.jp
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered
iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron …
iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - oak.novartis.com
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in
serious complications in the absence of chelation treatment to remove excess iron …
serious complications in the absence of chelation treatment to remove excess iron …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
AG Piga, R Galanello, G Forni, M Cappellini, R Origa… - …, 2006 - iris.unito.it
BACKGROUND AND OBJECTIVES: Iron accumulation is an inevitable consequence of
chronic blood transfusions and results in serious complications in the absence of chelation …
chronic blood transfusions and results in serious complications in the absence of chelation …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - europepmc.org
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in
serious complications in the absence of chelation treatment to remove excess iron …
serious complications in the absence of chelation treatment to remove excess iron …
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with …
A Piga, R Galanello, GL Forni, MD Cappellini… - …, 2006 - iris.unica.it
Iron accumulation is an inevitable consequence of chronic blood transfusions and results in
serious complications in the absence of chelation treatment to remove excess iron …
serious complications in the absence of chelation treatment to remove excess iron …